Skip to content
Study details
Enrolling now

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

University of Nebraska
NCT IDNCT03414502ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

400

Study length

about 21 years

Ages

19+

Locations

1 site in NE

What this study is about

This trial is testing a treatment for rheumatoid arthritis (RA) using different medications called DMARDs. The goal is to find out what factors help predict how well people respond to these medications. Participants will receive a starting dose of one or more DMARD medications, which may be adjusted by the doctor as needed.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Abatacept
  • 2.Take Adalimumab
  • 3.Take Azathioprine
  • +3 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

abatacept, adalimumab (Monoclonal antibody; blocks TNF-alpha to reduce inflammation), azathioprine (Antimetabolite; inhibits DNA synthesis in immune cells), baricitinib, certolizumab pegol, etanercept (TNF inhibitor (fusion protein capturing TNF-alpha)), golimumab, hydroxychloroquine (Antimalarial; increases pH in parasite)

Drug routes

injection, intravenous, oral (Oral Tablet), oral, infusion, oral (Delayed Release Oral Tablet)

Body systems

Immune